β-arrestin-2 predicts the clinical response to β-blockers in cirrhotic portal hypertension patients: A prospective study

Figure 1 The statistical analysis subsequently focused on β-Arr-2 expression in the gastric antrum. Cytoplasmic staining of β-Arrestin-2 (× 40) showing (A, B, C) low, moderate, and strong expression in the gastric antrum; (D, E) moderate and strong expression in the gastric body; and (F) strong expression in the duodenum respectively.

Figure 2 The statistical analysis subsequently focused on β-Arr-2 expression in the gastric antrum. A: Comparison between nonselective β-blockers (NSBB) responders and non-responders as regards β-Arrestin-2 expression, ^aP < 0.001; ^bP = 0.23; ^cP = 0.40; B: The frequency of small, medium, and large esophageal varices according to different intensities of β-Arrestin-2 expression at baseline; C: Comparison between NSBB responders and Non-responders as regards the changes in the frequency of low, medium, and large esophageal varices before and after treatment; D: Comparison between NSBB responders and Non-responders as regards the changes in the frequency of low, moderate, and strong antral β-Arrestin-2 expression before and after treatment. EV: Esophageal varices; NSBB: Nonselective beta-blockers.

Figure 3  A receiver operating characteristic curve analysis of serum β-Arrestin-2 Levels to identify patients with a low likelihood of variceal bleeding.

Figure 4 The cumulative incidence rates of variceal bleeding among NSBB non-responders group concerning. A: Baseline β-Arrestin-2 (β-Arr-2) antral expression; B: serum β-Arr-2 levels.